The Journal of allergy and clinical immunology
-
J. Allergy Clin. Immunol. · Aug 2011
Randomized Controlled Trial Comparative StudyTiotropium is noninferior to salmeterol in maintaining improved lung function in B16-Arg/Arg patients with asthma.
The efficacy and safety of inhaled long-acting β(2)-adrenergic agonists in asthmatic patients with the B16-Arg/Arg genotype has been questioned, and the use of antimuscarinics has been proposed as an alternative in patients whose symptoms are not controlled by inhaled corticosteroids (ICSs). ⋯ Tiotropium was more effective than placebo and as effective as salmeterol in maintaining improved lung function in B16-Arg/Arg patients with moderate persistent asthma. Safety profiles were comparable.
-
J. Allergy Clin. Immunol. · Aug 2011
Randomized Controlled TrialTiotropium improves lung function in patients with severe uncontrolled asthma: a randomized controlled trial.
Some patients with severe asthma remain symptomatic and obstructed despite maximal recommended treatment. Tiotropium, a long-acting inhaled anticholinergic agent, might be an effective bronchodilator in such patients. ⋯ The addition of once-daily tiotropium to asthma treatment, including a high-dose inhaled corticosteroid plus a long-acting β₂-agonist, significantly improves lung function over 24 hours in patients with inadequately controlled, severe, persistent asthma.